Trade AstraZeneca PLC - GBP - AZNl CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.28
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment£1,000.00Overnight funding adjustmentCharges from full value of position-0.02127 %(-£4.25)Trade size with leverage ~ £20,000.00Money from leverage ~ $£19,000.00Go to platform: -0.02127%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment£1,000.00Overnight funding adjustmentCharges from full value of position-0.00064 %(-£0.13)Trade size with leverage ~ £20,000.00Money from leverage ~ $£19,000.00Go to platform: -0.00064%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: GBP
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: Great Britain
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: £1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02127 %
  (-£4.25)

• Margin. Your investment: £1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00064 %
  (-£0.13)

Key Stats

• Prev. Close: 126.83
• Open: 125.35
• 1-Year Change: -1.03%
• Day's Range: 124.09 - 125.35

Trade AstraZeneca PLC - GBP - AZNl

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.